GB-115 vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Also: Cibinetide, ARA 290
An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | GB-115 | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GB-115 works by blocking central cholecystokinin-1 (CCK-1) receptors in the brain. CCK is involved in anxiety, panic responses, and cognitive modulation. By antagonizing these receptors, GB-115 reduces anxiety while improving attention, processing speed, and reaction time. It also modulates dopaminergic pathways involved in focus and motivation. | ARA-290 selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (β common receptor). This receptor is expressed on damaged and inflamed tissues. Activation triggers anti-apoptotic, anti-inflammatory, and tissue-protective pathways without stimulating red blood cell production. |
| Common Dosing | 6 mg daily (2 mg three times daily) 2-3 times daily (morning, afternoon, evening) | 4 mg daily Once daily |
| Administration | Oral tablets or sublingual | Subcutaneous injection |
| Typical Duration | 21+ days in clinical trials, effects noted by day 7 | 28-day courses in trials |
| Best Time to Take | Morning and throughout the day | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical studies in patients with Generalized Anxiety Disorder (GAD) showed GB-115 (6mg/day) significantly improved reaction time, attention, and processing speed within 7 days of treatment. A 21-day trial with 31 patients demonstrated anxiolytic effects comparable to benzodiazepines without sedation or dependency. Currently in Phase II/III trials (NCT05586789) for anxiety disorders. Anecdotal reports suggest benefits for ADHD symptoms, though direct ADHD trials are pending. | Phase II/III clinical trials for diabetic neuropathy show improvement in corneal nerve fiber density and small fiber function. Orphan Drug Designation granted in both US and EU for sarcoidosis treatment. Studies demonstrate efficacy in small fiber neuropathy, neuropathic pain, and sarcoidosis-related symptoms. Being developed by Araim Pharmaceuticals. |
Frequently Asked Questions: GB-115 vs ARA-290
What is the difference between GB-115 and ARA-290?
GB-115 is a cognitive peptide that a dipeptide anxiolytic and nootropic that acts as a cck-1 (cholecystokinin) receptor antagonist. developed in russia with completed phase 3 trials for anxiety. users report significant improvements in focus, attention, and adhd-like symptoms. ARA-290 is a cognitive peptide that an 11-amino acid peptide derived from erythropoietin (epo) that activates the innate repair receptor. unlike epo, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GB-115 or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. GB-115 is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GB-115 and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GB-115 and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of GB-115 and ARA-290 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.